Lab-Grown Coronary Bypass Graft: 2-Year Patency<\/p>\n
Source: EACTS 2026 Annual Meeting, Barcelona | October 7\u201310, 2026<\/p>\n
\u2022\u2060 \u2060Bioengineered human blood vessel developed as a potential CABG conduit.
\n\u2022\u2060 \u2060Human tissue vessels are grown in a bioreactor, then decellularized, leaving a natural collagen-based scaffold that can be stored until needed.
\n\u2022\u2060 \u2060After implantation, the patient\u2019s own cells repopulate and endothelialize the graft, progressively converting it into living tissue.
\n\u2022\u2060 \u2060First reported CABG patient: graft remained patent with normal flow at 2 years, the longest reported clinical patency for this Vascudyne tissue-engineered vessel.
\n\u2022\u2060 \u2060No reported graft thrombosis, aneurysmal dilation, bleeding, major cardiac events, or device-related adverse events in this case.
\n\u2022\u2060 \u2060Potential advantage: an immediately available conduit that could avoid saphenous-vein harvesting and the second surgical wound.
\n\u2022\u2060 \u2060Important: this remains very early clinical evidence from a single reported patient; larger studies are required to establish long-term patency, safety, and comparison with established arterial\/venous conduits.
\n\u2022\u2060 \u2060A European CABG feasibility study has completed enrollment.<\/p>\n